Related Experiment Videos
TCL1: a new drug target in lymphoid and germ-cell malignancies?
1Children's Cancer Institute Australia for Medical Research, NSW 2031, Randwick, Australia. richard.lock@unsw.edu.au
Abstract:
The protein product of the T-cell leukemia/lymphoma 1 (TCL1) oncogene was recently identified as a novel Akt kinase activator. Its crystal structure predicts regions most likely involved in protein-protein interactions, and complex formation is required for TCL1 to activate Akt. TCL1 is expressed in a broad range of normal and malignant lymphoid cell types and in a high proportion of testicular seminomas of germ cell origin, indicating its potential to serve as a novel anti-cancer drug target. This review is focused on the current state of knowledge of TCL1 and the medical implications of its discovery.
Insights
The T-cell leukemia/lymphoma 1 (TCL1) oncogene protein activates Akt kinase. This protein
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The T-cell leukemia/lymphoma 1 (TCL1) oncogene encodes a protein.
- TCL1 protein is a novel activator of Akt kinase.
- Protein-protein interactions are crucial for TCL1 to activate Akt.
Purpose of the Study:
- To review the current knowledge of TCL1.
- To discuss the medical implications of TCL1 discovery.
Main Methods:
- Literature review of TCL1 research.
- Analysis of TCL1 crystal structure.
- Examination of TCL1 expression patterns.
Main Results:
- TCL1 protein activates Akt kinase.
- TCL1 forms complexes required for Akt activation.
- TCL1 is expressed in lymphoid cells and testicular germ cell tumors.
Conclusions:
- TCL1's role in Akt activation is significant.
- TCL1's expression in tumors suggests its potential as an anti-cancer drug target.